期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 26, 期 4, 页码 329-334出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2014.991673
关键词
Acitretin; ciclosporin; fumaric acid esters; methotrexate; pregnancy
类别
资金
- Abbott/AbbVie
- Almirall-Hermal
- Amgen
- BASF
- Biogen Idec
- Celgene
- Centocor
- Eli Lilly
- Forward Pharma
- Galderma
- Janssen
- Leo Pharma
- Medac
- MSD
- Miltenyi Biotech
- Novartis
- Pfizer
- Teva
- VBL
- Xenoport
- Abbvie
- Actelion
- GSK-Stiefel
- Sandoz
- Trident
- UCB
The effects of conventional systemic therapies for psoriasis on pregnancy outcomes, lactation, male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide clinician and patient. In this study, we review the safety profile of the commonly used conventional systemic therapies used for psoriasis in individuals of reproductive potential. Safety data are derived from large-scale registries, adverse-event reporting databases, clinical trials and case reports. We assess the effect of each therapy on adverse pregnancy outcomes, including congenital malformations, and lactation with maternal administration. We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据